HRP20201785T1 - Multivalentni i multispecifični fuzijski proteini koji vežu dr5 - Google Patents
Multivalentni i multispecifični fuzijski proteini koji vežu dr5 Download PDFInfo
- Publication number
- HRP20201785T1 HRP20201785T1 HRP20201785TT HRP20201785T HRP20201785T1 HR P20201785 T1 HRP20201785 T1 HR P20201785T1 HR P20201785T T HRP20201785T T HR P20201785TT HR P20201785 T HRP20201785 T HR P20201785T HR P20201785 T1 HRP20201785 T1 HR P20201785T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- isolated polypeptide
- dr5bd
- polypeptide according
- seq
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Claims (16)
1. Izolirani polipeptid, naznačen time, da veže najmanje jedan mortalni receptor 5 (DR5) i obuhvaća veći broj DR5 vezujućih domena (DR5BD), pri čemu svaka DR5BD je VHH, dok svaka VHH sadrži aminokiselinski slijed odabran iz skupine koja se sastoji od SEQ ID NO: 87, 89 i 17-20.
2. Izolirani polipeptid prema patentnom zahtjevu 1, naznačen time, da je izolirani polipeptid monospecifičan.
3. Izolirani polipeptid prema patentnom zahtjevu 1, naznačen time, da je izolirani polipeptid monospecifičan ili bispecifičan; ili time, da polipeptid obuhvaća barem jednu drugu vezujuću domenu (BD2) koja veže drugi antigen.
4. Izolirani polipeptid prema patentnom zahtjevu 1, naznačen time, da veći broj DR5BD, sadrži najmanje dvije DR5BD, najmanje četiri DR5BD, ili najmanje šest DR5BD.
5. Izolirani polipeptid prema patentnom zahtjevu 1, naznačen time, da svaka DR5BD od većeg broja DR5BD, obuhvaća isti aminokiselinski slijed odabran iz skupine koja se sastoji od SEQ ID NO: 87, 89 i 17-20.
6. Izolirani polipeptid prema patentnom zahtjevu 1, naznačen time, da izolirani polipeptid obuhvaća polipeptid Fc regije imunoglobulina; i/ili time, da imunoglobulin je polipeptid Fc regije IgG1, polipeptid Fc regije IgG2, polipeptid Fc regije IgG3, ili polipeptid Fc regije IgG4.
7. Izolirani polipeptid prema patentnom zahtjevu 6, naznačen time, da polipeptid Fc regije imunoglobulina obuhvaća aminokiselinski slijed odabran iz skupine koja se sastoji od SEQ ID NO: 1-5 ili 127.
8. Izolirani polipeptid prema patentnom zahtjevu 6, naznačen time, da polipeptid Fc regije imunoglobulina obuhvaća aminokiselinski slijed od SEQ ID NO: 2.
9. Izolirani polipeptid prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da VHH je humanizirani VHH.
10. Izolirani polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid je tetravalentan i obuhvaća sljedeću strukturu: DR5BD-Povezivač-DR5BD-Povezivač-Zglob-Fc, pri čemu DR5BD je humanizirani VHH slijed.
11. Izolirani polipeptid prema patentnom zahtjevu 10, naznačen time, da polipeptid obuhvaća dvije kopije aminokiselinskog slijeda od SEQ ID NO: 87.
12. Izolirani polipeptid prema patentnom zahtjevu 10, naznačen time, da polipeptid obuhvaća aminokiselinski slijed odabran iz skupine koja se sastoji od SEQ ID NO: 113 i 115.
13. Izolirani polipeptid prema patentnom zahtjevu 10, naznačen time, da polipeptid obuhvaća aminokiselinski slijed od SEQ ID NO: 113.
14. Izolirani polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid je heksavalentan i obuhvaća sljedeću strukturu: DR5BD-Povezivač-DR5BD-Povezivač-DR5BD-Povezivač-Zglob-Fc, pri čemu DR5BD je humanizirani VHH slijed.
15. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da se upotrebljava u liječenju neoplazmi, pri čemu je neoplazma prvenstveno rak.
16. Polipeptid za uporabu prema patentnom zahtjevu 15, naznačen time, da se upotrebljava u moduliranju imunoloških stanica, u svrhu pojačavanja razgradnje tumora.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193309P | 2015-07-16 | 2015-07-16 | |
| PCT/US2016/042862 WO2017011837A2 (en) | 2015-07-16 | 2016-07-18 | Multivalent and multispecific dr5-binding fusion proteins |
| EP16825315.1A EP3322734B1 (en) | 2015-07-16 | 2016-07-18 | Multivalent and multispecific dr5-binding fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201785T1 true HRP20201785T1 (hr) | 2021-01-22 |
Family
ID=57757772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201785TT HRP20201785T1 (hr) | 2015-07-16 | 2020-11-06 | Multivalentni i multispecifični fuzijski proteini koji vežu dr5 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10308720B2 (hr) |
| EP (2) | EP3798232A1 (hr) |
| JP (3) | JP6807606B2 (hr) |
| KR (1) | KR20180030518A (hr) |
| CN (2) | CN114106178A (hr) |
| AU (2) | AU2016291701B2 (hr) |
| BR (1) | BR112018000584A2 (hr) |
| CA (1) | CA2991634A1 (hr) |
| CY (1) | CY1123615T1 (hr) |
| DK (1) | DK3322734T3 (hr) |
| ES (1) | ES2833773T3 (hr) |
| HK (1) | HK1254433A1 (hr) |
| HR (1) | HRP20201785T1 (hr) |
| HU (1) | HUE051896T2 (hr) |
| IL (3) | IL292037A (hr) |
| LT (1) | LT3322734T (hr) |
| MX (2) | MX2018000523A (hr) |
| PL (1) | PL3322734T3 (hr) |
| PT (1) | PT3322734T (hr) |
| RS (1) | RS61062B1 (hr) |
| RU (2) | RU2748620C2 (hr) |
| SG (1) | SG10201912410TA (hr) |
| SI (1) | SI3322734T1 (hr) |
| WO (1) | WO2017011837A2 (hr) |
| ZA (1) | ZA201800238B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| EP3732197A1 (en) * | 2017-12-28 | 2020-11-04 | Julius-Maximilians-Universität Würzburg | TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA) |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| WO2020047705A1 (zh) * | 2018-09-03 | 2020-03-12 | 安菲尼生命科技有限公司 | Dr5单域抗体及其用途 |
| EP4294842A1 (en) * | 2021-02-19 | 2023-12-27 | Inhibrx, Inc. | Formulations of dr5 binding polypeptides |
| TW202404636A (zh) * | 2022-04-08 | 2024-02-01 | 美商英伊布里克斯公司 | Dr5促效劑及plk1抑制劑或cdk抑制劑之組合療法 |
| WO2023230432A1 (en) * | 2022-05-23 | 2023-11-30 | Inhibrx, Inc. | Dr5 agonist and iap antagonist combination therapy |
| WO2024069180A2 (en) | 2022-09-28 | 2024-04-04 | LiliumX Ltd. | Multivalent proteins and screening methods |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992011272A1 (en) * | 1990-12-20 | 1992-07-09 | Ixsys, Inc. | Optimization of binding proteins |
| US20020147140A1 (en) * | 2000-01-31 | 2002-10-10 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| KR20070010046A (ko) | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| AU2005323025A1 (en) | 2004-12-31 | 2006-07-13 | Biogen Idec Ma Inc. | Polypeptides that bind BR3 and uses thereof |
| US20090075832A1 (en) | 2005-02-24 | 2009-03-19 | Cemines, Inc | Compositions and Methods for Classifying Biological Samples |
| US8124076B2 (en) | 2005-08-18 | 2012-02-28 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against β-amyloid peptide |
| US20100056439A1 (en) | 2005-12-06 | 2010-03-04 | Domantis Limited | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| DK1987178T3 (en) | 2006-02-20 | 2015-04-20 | Phylogica Ltd | Process for the construction and screening of peptide structure libraries |
| JP2008133206A (ja) | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
| EA201000903A1 (ru) | 2007-11-30 | 2011-02-28 | Калобиос Фармасьютикалс, Инк. | Антитела к pcrv-антигену pseudomonas aeruginosa |
| DK2285408T3 (en) * | 2008-06-05 | 2019-02-04 | Ablynx Nv | AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES |
| US20110166076A1 (en) | 2008-09-10 | 2011-07-07 | Bac Ip B.V. | Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases |
| WO2010107778A1 (en) | 2009-03-18 | 2010-09-23 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
| US20100281003A1 (en) | 2009-04-02 | 2010-11-04 | New York University | System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions |
| CN101717775B (zh) * | 2009-11-13 | 2012-01-04 | 厦门大学 | 抗人死亡受体5的单链抗体基因 |
| EP2513145B1 (en) | 2009-12-14 | 2018-01-24 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
| US9120855B2 (en) * | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| US8623369B2 (en) | 2010-04-27 | 2014-01-07 | National Research Council Of Canada | Anti-ICAM-1 single domain antibody and uses thereof |
| RU2595839C2 (ru) | 2010-09-27 | 2016-08-27 | МорфоСис АГ | Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl |
| EP2632949B1 (en) | 2010-10-25 | 2017-09-13 | National Research Council of Canada | Clostridium difficile-specific antibodies and uses thereof |
| CA2822684A1 (en) | 2010-12-23 | 2012-06-28 | Intercell Austria Ag | Oprf/i agents and their use in hospitalized and other patients |
| TW201321405A (zh) | 2011-08-17 | 2013-06-01 | Glaxo Group Ltd | 經修飾之蛋白質及肽 |
| JP6163158B2 (ja) | 2011-10-13 | 2017-07-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ４０ｌに拮抗する抗体ポリペプチド |
| JP2014533249A (ja) | 2011-11-07 | 2014-12-11 | メディミューン，エルエルシー | 多重特異性を持つ多価結合タンパク質およびその使用 |
| WO2013091103A1 (en) | 2011-12-20 | 2013-06-27 | Adaerata, Limited Partnership | Single domain antibodies as inhibitors of pcsk9 |
| KR20140132748A (ko) | 2012-03-02 | 2014-11-18 | 아블린쓰 엔.브이. | 슈도모나스 애루기노사 pcrv 결합 단일 가변 도메인 항체 |
| WO2013167883A1 (en) | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| CN104781277A (zh) | 2012-09-13 | 2015-07-15 | 诺华股份有限公司 | 具有末端修饰的抗原结合分子 |
| MX2015005719A (es) | 2012-11-06 | 2016-01-12 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
| CN102924600B (zh) * | 2012-11-14 | 2013-10-30 | 河南大学 | 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用 |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| EP3004170A1 (en) | 2013-05-28 | 2016-04-13 | VIB vzw | Single domain antibodies against sod1 and their use in medicine |
| WO2015104994A1 (ja) * | 2014-01-10 | 2015-07-16 | 学校法人帝京平成大学 | 組換え偏性嫌気性グラム陽性菌 |
-
2016
- 2016-07-18 KR KR1020187000975A patent/KR20180030518A/ko not_active Application Discontinuation
- 2016-07-18 ES ES16825315T patent/ES2833773T3/es active Active
- 2016-07-18 IL IL292037A patent/IL292037A/en unknown
- 2016-07-18 CA CA2991634A patent/CA2991634A1/en active Pending
- 2016-07-18 LT LTEP16825315.1T patent/LT3322734T/lt unknown
- 2016-07-18 DK DK16825315.1T patent/DK3322734T3/da active
- 2016-07-18 US US15/213,296 patent/US10308720B2/en active Active
- 2016-07-18 BR BR112018000584A patent/BR112018000584A2/pt active Search and Examination
- 2016-07-18 PL PL16825315T patent/PL3322734T3/pl unknown
- 2016-07-18 EP EP20189995.2A patent/EP3798232A1/en active Pending
- 2016-07-18 RS RS20201315A patent/RS61062B1/sr unknown
- 2016-07-18 HU HUE16825315A patent/HUE051896T2/hu unknown
- 2016-07-18 MX MX2018000523A patent/MX2018000523A/es unknown
- 2016-07-18 AU AU2016291701A patent/AU2016291701B2/en active Active
- 2016-07-18 EP EP16825315.1A patent/EP3322734B1/en active Active
- 2016-07-18 RU RU2018102803A patent/RU2748620C2/ru active
- 2016-07-18 WO PCT/US2016/042862 patent/WO2017011837A2/en active Application Filing
- 2016-07-18 CN CN202111039963.9A patent/CN114106178A/zh active Pending
- 2016-07-18 IL IL307994A patent/IL307994A/en unknown
- 2016-07-18 JP JP2018501345A patent/JP6807606B2/ja active Active
- 2016-07-18 RU RU2021111382A patent/RU2021111382A/ru unknown
- 2016-07-18 PT PT168253151T patent/PT3322734T/pt unknown
- 2016-07-18 SG SG10201912410TA patent/SG10201912410TA/en unknown
- 2016-07-18 CN CN201680041274.2A patent/CN107922491B/zh active Active
- 2016-07-18 SI SI201631005T patent/SI3322734T1/sl unknown
-
2018
- 2018-01-07 IL IL256772A patent/IL256772B/en unknown
- 2018-01-12 ZA ZA2018/00238A patent/ZA201800238B/en unknown
- 2018-01-12 MX MX2023002379A patent/MX2023002379A/es unknown
- 2018-10-22 HK HK18113517.7A patent/HK1254433A1/zh unknown
-
2019
- 2019-04-18 US US16/387,754 patent/US11117973B2/en active Active
-
2020
- 2020-11-06 HR HRP20201785TT patent/HRP20201785T1/hr unknown
- 2020-11-16 CY CY20201101085T patent/CY1123615T1/el unknown
- 2020-11-26 JP JP2020196358A patent/JP7244938B2/ja active Active
-
2021
- 2021-08-05 US US17/394,900 patent/US11976126B2/en active Active
-
2022
- 2022-11-30 JP JP2022191038A patent/JP2023022214A/ja active Pending
- 2022-12-21 AU AU2022291498A patent/AU2022291498A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201785T1 (hr) | Multivalentni i multispecifični fuzijski proteini koji vežu dr5 | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| IL259927B1 (en) | Humanized antibodies against cd73 | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
| HRP20202024T1 (hr) | Cd3-vežuća domena | |
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| HRP20210364T1 (hr) | Anti-gitr antitijela i postupci za njihovu primjenu | |
| HRP20210372T1 (hr) | Anti-lag3 antitijela i antigen-vezujući fragmenti | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| PE20231067A1 (es) | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos | |
| HRP20210977T1 (hr) | Ciljano inhibiranje tgf beta | |
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| HRP20220629T1 (hr) | Anti-cd73 antitijela i njihove upotrebe | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2018523493A5 (hr) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JOP20180042A1 (ar) | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام | |
| JP2018520650A5 (hr) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2016536322A5 (hr) | ||
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| JP2018518540A5 (hr) |